Published in
BMJ Publishing Group, Gut, 7(20), p. 624-628, 1979
DOI: 10.1136/gut.20.7.624
Links
- ORCID
- BMJ Publishing Group
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net]
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Double-blind randomised clinical trial of a pepsin-inhibitory pentapeptide (pepstatin) in the treatment of duodenal ulcer.
Journal article published in 1979 by
O. Bonnevie,
J. Søltoft,
L. B. Svendsen 
,
J. Holst-Christensen,
T. S. Johansen,
J. Soltoft,
P. M. Christiansen
,
J. Holst-Christensen,
T. S. Johansen,
J. Soltoft,
P. M. Christiansen
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
In a double-blind randomised clinical trial a specific inhibition of peptic activity with a pentapeptide, pepstatin, had no significant advantage over placebo in the ulcer healing and symptomatology of duodenal ulcer. Thus, the inhibition of pepsin in human gastric juice does not appear to have a major influence on the healing of duodenal ulcer.